N-Acetyl Selank Amidate
N-Acetyl-Thr-Lys-Pro-Arg-Pro-Gly-Pro-NH2 (N-acetylated, C-terminal amidated analog of Selank/TP-7)
N-Acetyl Selank Amidate is a stabilized synthetic derivative of Selank (TP-7), modified with N-terminal acetylation and C-terminal amidation to enhance proteolytic stability and bioavailability. It is investigated for anxiolytic, nootropic, and neuroprotective effects via GABAA allosteric modulation, enkephalin enzyme inhibition, and BDNF upregulation. There are no human clinical trials for this specific derivative; its profile is entirely inferred from studies on the parent compound Selank (PMID: 18454096, PMC4757669).
Last updated: 2026-03-12
Safety Summary
Safety data is primarily extrapolated from the parent compound Selank, not from direct NA-Selank-Amidate studies. Published Selank clinical trials (sample sizes ~60-70 patients, durations up to ~1 month) reported no treatment-related serious adverse events and no dose-limiting toxicities (PMID: 25176261, PMID: 26356395). No FAERS or EudraVigilance safety signals found for NA-Selank-Amidate as of March 2026. No chronic toxicology, carcinogenicity, reproductive toxicology, or organ-impairment studies have been published. Preclinical rodent data for Selank show no tolerance, tachyphylaxis, withdrawal effects, or dependence signals (PMC5322660; PMID: 24913576). The absence of long-term safety data should NOT be interpreted as evidence of absence of risk.
Known Side Effects
Common
Occasional
Rare
Occasional
Rare
Who Should NOT Use This
Per the Russian Selank product label (RLS: rlsnet.ru/drugs/selank-36612). Applied by extension.
Contraindicated per Russian Selank label due to lack of clinical safety data. No reproductive toxicology data for NA-Selank-Amidate.
Contraindicated per Russian Selank label due to lack of clinical safety data during breastfeeding.
Not recommended due to lack of clinical data (Russian Selank label).
No published clinical guidance, dose-adjustment recommendations, or safety data in patients with renal or hepatic dysfunction for either Selank or NA-Selank-Amidate.
Talk to Your Doctor
Before considering N-Acetyl Selank Amidate, discuss it with your healthcare provider. Ask about potential interactions with your current medications, whether it is appropriate for your health conditions, and what monitoring may be needed.
Sources: [1-11]
Evidence Assessment
Evidence tier 5 (preclinical/research only). NA-Selank-Amidate has NO published human clinical trials. No registered clinical trials were found in ClinicalTrials.gov, WHO ICTRP, EU Clinical Trials Register, or Russian registries. Two ClinicalTrials.gov entries (NCT05905055, NCT06565208) exist but have no posted protocols or results. The parent compound Selank has limited human RCT data (n=62, Zozulia et al., 2008 -- PMID:18454096; n=70, Medvedev et al., 2015 -- PMID:26356395) and is approved in Russia, but NA-Selank-Amidate is a distinct chemical entity with no independent human efficacy or safety data. All human-relevant evidence is extrapolated from the parent compound.
1Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurastheniaPMID 18454096
Zozulia AA, Neznamov GG, Siuniakov TS, et al. - Zh Nevrol Psikhiatr Im S S Korsakova (Russian) (2008) - Randomized controlled trial - 62
Selank demonstrated anxiolytic efficacy comparable to medazepam in patients with GAD and neurasthenia, with additional antiasthenic/nootropic effects. NOTE: Tests Selank, NOT NA-Selank-Amidate.
Limitations: Small sample size. Single-center Russian study. Tests Selank parent compound, not NA-Selank-Amidate.
2Optimization of the treatment of anxiety disorders with selankPMID 26356395
Medvedev VE, Tereshchenko ON, Kost NV, et al. - Zh Nevrol Psikhiatr Im S S Korsakova (2015) - Randomized controlled trial (comparative) - 70
Selank + phenazepam accelerated therapeutic effect onset and reduced benzodiazepine side effects. NOTE: Tests Selank, NOT NA-Selank-Amidate.
Limitations: Not placebo-controlled. Tests Selank as adjunct. Russian-language publication.
3A comparison of the anxiolytic effect and tolerability of selank and phenazepamPMID 25176261
Not specified in source - Not specified in source - Comparative clinical study
Selank showed good tolerability with predominantly mild, local adverse effects. No treatment-related SAEs or dose-limiting toxicities. NOTE: Tests Selank, NOT NA-Selank-Amidate.
Limitations: Details not fully extractable. Tests Selank parent compound.
4Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission
Volkova et al. - Frontiers in Pharmacology (2016) - Preclinical in vivo (rat)
Selank altered expression of genes involved in GABAergic neurotransmission in rat frontal cortex. NOTE: Tests Selank, NOT NA-Selank-Amidate.
Limitations: Animal study. Tests Selank parent compound.
5Common and Specific Effects of Selank on the Glycine Site of the NMDA Receptor in Mice
Vasil'eva et al. - Neurochemical Journal (2023) - Preclinical in vivo (mice)
Selank modulates the glycine binding site of NMDA receptors with strain- and region-dependent effects. NOTE: Tests Selank, NOT NA-Selank-Amidate.
Limitations: Animal study. Strain-specific effects. Tests Selank parent compound.
6Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats
Kasian et al. - Behavioural Neurology (2017) - Preclinical in vivo (rat chronic stress model)
Selank enhanced diazepam's anxiolytic effect. No tolerance or tachyphylaxis observed. NOTE: Tests Selank, NOT NA-Selank-Amidate.
Limitations: Animal study. Tests Selank parent compound.
7Efficacy of peptide anxiolytic selank during modeling of withdrawal syndrome in rats with stable alcoholic motivationPMID 24913576
Not specified in source - Not specified in source - Preclinical in vivo (rat alcohol withdrawal model)
Selank alleviated alcohol-withdrawal anxiety without producing its own discontinuation syndrome. No dependence or rebound. NOTE: Tests Selank, NOT NA-Selank-Amidate.
Limitations: Animal study. Tests Selank parent compound.
8Semax and Selank Inhibit the Enkephalin-Degrading Enzymes of Human Serum
Not specified in source - Bulletin of Experimental Biology and Medicine - In vitro (human serum)
Both Semax and Selank inhibit enkephalin-degrading enzymes in human serum, increasing endogenous enkephalin availability. NOTE: Tests Selank, NOT NA-Selank-Amidate.
Limitations: In vitro study. Tests Selank parent compound.
9Gastroprotective effects of Selank (rodent ulcer model study)PMID 15835541
Pavlov et al. - Not specified in source (2005) - Preclinical in vivo (rodent gastric ulcer model)
Selank promoted ulcer healing and gastric mucosal integrity. NOTE: Tests Selank, NOT NA-Selank-Amidate.
Limitations: Animal study. Tests Selank parent compound.
10Acute hemodynamic effects of Selank in rodentsPMID 16193654
Gan'shina et al. - Not specified in source (2005) - Preclinical in vivo (rodent acute pharmacology)
Selank produced ~32% decrease in arterial pressure and ~24% increase in cerebral blood flow in rodents. NOTE: Tests Selank, NOT NA-Selank-Amidate.
Limitations: Acute animal pharmacology. Tests Selank parent compound.
11Immunomodulatory effects of selank in patients with anxiety-asthenic disorders
Not specified in source - Not specified in source - Clinical study (human)
Selank demonstrated immunomodulatory effects including IL-6 modulation in patients with anxiety-asthenic disorders. NOTE: Tests Selank, NOT NA-Selank-Amidate.
Limitations: Details limited. Tests Selank parent compound.